MX336498B - Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores alk. - Google Patents
Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores alk.Info
- Publication number
- MX336498B MX336498B MX2012008914A MX2012008914A MX336498B MX 336498 B MX336498 B MX 336498B MX 2012008914 A MX2012008914 A MX 2012008914A MX 2012008914 A MX2012008914 A MX 2012008914A MX 336498 B MX336498 B MX 336498B
- Authority
- MX
- Mexico
- Prior art keywords
- innate
- cancers
- assessment
- therapy
- identification
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33746510P | 2010-02-04 | 2010-02-04 | |
| PCT/IB2011/000382 WO2011095894A2 (en) | 2010-02-04 | 2011-02-04 | Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012008914A MX2012008914A (es) | 2012-11-30 |
| MX336498B true MX336498B (es) | 2016-01-21 |
Family
ID=44355876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008914A MX336498B (es) | 2010-02-04 | 2011-02-04 | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores alk. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9018230B2 (enExample) |
| EP (1) | EP2531858B1 (enExample) |
| JP (1) | JP5937017B2 (enExample) |
| KR (1) | KR101843967B1 (enExample) |
| CN (2) | CN103937877B (enExample) |
| AR (1) | AR080361A1 (enExample) |
| AU (1) | AU2011212165B2 (enExample) |
| BR (1) | BR112012019215A2 (enExample) |
| CA (1) | CA2786974C (enExample) |
| ES (1) | ES2660149T3 (enExample) |
| MX (1) | MX336498B (enExample) |
| NZ (1) | NZ601606A (enExample) |
| RU (1) | RU2589834C2 (enExample) |
| SG (1) | SG182766A1 (enExample) |
| TW (1) | TWI518325B (enExample) |
| WO (1) | WO2011095894A2 (enExample) |
| ZA (1) | ZA201205831B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383793B2 (en) * | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
| JP6205216B2 (ja) | 2012-09-24 | 2017-09-27 | アークレイ株式会社 | 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット |
| US9428812B2 (en) * | 2014-04-28 | 2016-08-30 | Insight Genetics, Inc. | Kit comprising primers for amplifying ALK kinase domain nucleic acids |
| DK3186284T3 (da) * | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| JP2019519540A (ja) * | 2016-06-01 | 2019-07-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 肺癌患者におけるａｌｋ阻害薬療法に対する応答を予測する未分化リンパ腫キナーゼにおける新規な変異 |
| KR101872624B1 (ko) * | 2016-12-27 | 2018-06-28 | (주) 바이오인프라생명과학 | Alk 표적 치료제에 대한 폐암의 치료 반응성을 예측하는 방법 |
| CN107828823A (zh) * | 2017-09-29 | 2018-03-23 | 暨南大学 | 一种评价eml4‑alk抑制剂对肺癌治疗效果的方法 |
| RU2717309C2 (ru) * | 2018-08-01 | 2020-03-20 | Общество с ограниченной ответственностью "ОНКОДИАГНОСТИКА АТЛАС" | Способ определения микросателлитной нестабильности |
| CN112424380B (zh) | 2018-11-01 | 2025-03-04 | Illumina公司 | 用于体细胞变体检测的方法和组合物 |
| EP4139440B1 (en) | 2020-04-22 | 2026-08-19 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| CA3195019A1 (en) | 2020-10-06 | 2022-04-14 | Maria Fardis | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2024017352A1 (zh) * | 2022-07-22 | 2024-01-25 | 四川大学 | 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3751873T2 (de) | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4998617A (en) | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| ATE138106T1 (de) | 1988-07-20 | 1996-06-15 | David Segev | Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ZA899593B (en) | 1988-12-16 | 1990-09-26 | Siska Diagnostics Inc | Self-sustained,sequence replication system |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| IE66597B1 (en) | 1989-05-10 | 1996-01-24 | Akzo Nv | Method for the synthesis of ribonucleic acid (RNA) |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| DE69034263D1 (de) | 1989-07-25 | 2009-04-02 | Cell Genesys Inc | Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992000968A1 (en) | 1990-07-10 | 1992-01-23 | Smithkline Beecham Corporation | Oxamides |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5491224A (en) | 1990-09-20 | 1996-02-13 | Bittner; Michael L. | Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture |
| US6277569B1 (en) | 1990-09-20 | 2001-08-21 | Vysis, Inc. | Methods for multiple direct label probe detection of multiple chromosomes or regions thereof by in situ hybridization |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
| JP2775346B2 (ja) | 1992-04-03 | 1998-07-16 | アプライド バイオシステムズ，インコーポレイテッド | プローブ構成物および方法 |
| FR2690691B1 (fr) | 1992-04-29 | 1999-02-12 | Bio Merieux | Procede d'amplification d'arn necessitant une seule etape de manipulation. |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| ATE267877T1 (de) | 1993-01-07 | 2004-06-15 | Sequenom Inc | Dns - sequenzierung durch massenspektronomie |
| JPH08507926A (ja) | 1993-03-19 | 1996-08-27 | シーケノム・インコーポレーテツド | エキソヌクレアーゼ分解を介した質量分析法によるｄｎａ配列決定 |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5571676A (en) | 1995-06-07 | 1996-11-05 | Ig Laboratories, Inc. | Method for mismatch-directed in vitro DNA sequencing |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6261775B1 (en) | 1999-04-09 | 2001-07-17 | The Regents Of The University Of California | Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma |
| CA2379264A1 (en) * | 1999-07-09 | 2001-01-18 | The Burnham Institute | A method for determining the prognosis of cancer patients by measuring levels of bag expression |
| PL1713806T3 (pl) * | 2004-02-14 | 2013-09-30 | Irm Llc | Związki i kompozycje jako inhibitory kinaz białkowych |
| WO2008127248A1 (en) | 2007-04-13 | 2008-10-23 | Cell Signaling Technology, Inc. | Gene defects and mutant alk kinase in human solid tumors |
| PL2450437T3 (pl) | 2006-04-14 | 2017-12-29 | Cell Signaling Technology Inc | Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych |
| WO2009103061A2 (en) * | 2008-02-15 | 2009-08-20 | The Children's Hospital Of Philadelphia | Methods and compositions for identifying, diagnosing, and treating neuroblastoma |
| US20110206691A1 (en) * | 2008-02-15 | 2011-08-25 | Mosse Yael P | Methods and Compositions for Treating Neuroblastoma |
| SG188802A1 (en) | 2008-03-06 | 2013-04-30 | Genentech Inc | Combination therapy with c-met and egfr antagonists |
| CA2762108A1 (en) * | 2009-05-15 | 2010-11-18 | Insight Genetics, Inc. | Methods and compositions relating to fusions of alk for diagnosing and treating cancer |
| US9031642B2 (en) | 2013-02-21 | 2015-05-12 | Medtronic, Inc. | Methods for simultaneous cardiac substrate mapping using spatial correlation maps between neighboring unipolar electrograms |
-
2011
- 2011-02-01 TW TW100103831A patent/TWI518325B/zh not_active IP Right Cessation
- 2011-02-02 AR ARP110100349A patent/AR080361A1/es active IP Right Grant
- 2011-02-04 EP EP11739469.2A patent/EP2531858B1/en not_active Not-in-force
- 2011-02-04 KR KR1020127022771A patent/KR101843967B1/ko not_active Expired - Fee Related
- 2011-02-04 SG SG2012055885A patent/SG182766A1/en unknown
- 2011-02-04 NZ NZ601606A patent/NZ601606A/en not_active IP Right Cessation
- 2011-02-04 CA CA2786974A patent/CA2786974C/en active Active
- 2011-02-04 JP JP2012551704A patent/JP5937017B2/ja not_active Expired - Fee Related
- 2011-02-04 ES ES11739469.2T patent/ES2660149T3/es active Active
- 2011-02-04 MX MX2012008914A patent/MX336498B/es unknown
- 2011-02-04 BR BR112012019215A patent/BR112012019215A2/pt not_active IP Right Cessation
- 2011-02-04 WO PCT/IB2011/000382 patent/WO2011095894A2/en not_active Ceased
- 2011-02-04 US US13/576,508 patent/US9018230B2/en active Active
- 2011-02-04 CN CN201410061691.6A patent/CN103937877B/zh not_active Expired - Fee Related
- 2011-02-04 AU AU2011212165A patent/AU2011212165B2/en not_active Ceased
- 2011-02-04 CN CN2011800058134A patent/CN102844664A/zh active Pending
- 2011-02-04 RU RU2012133318/15A patent/RU2589834C2/ru active
-
2012
- 2012-08-02 ZA ZA2012/05831A patent/ZA201205831B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR080361A1 (es) | 2012-04-04 |
| TW201144807A (en) | 2011-12-16 |
| RU2012133318A (ru) | 2014-03-10 |
| EP2531858B1 (en) | 2018-01-10 |
| SG182766A1 (en) | 2012-08-30 |
| EP2531858A2 (en) | 2012-12-12 |
| KR101843967B1 (ko) | 2018-03-30 |
| JP5937017B2 (ja) | 2016-06-22 |
| CA2786974A1 (en) | 2011-08-11 |
| US9018230B2 (en) | 2015-04-28 |
| AU2011212165A1 (en) | 2012-09-20 |
| RU2589834C2 (ru) | 2016-07-10 |
| HK1197922A1 (zh) | 2015-02-27 |
| TWI518325B (zh) | 2016-01-21 |
| CN102844664A (zh) | 2012-12-26 |
| NZ601606A (en) | 2014-06-27 |
| MX2012008914A (es) | 2012-11-30 |
| WO2011095894A2 (en) | 2011-08-11 |
| US20130203810A1 (en) | 2013-08-08 |
| BR112012019215A2 (pt) | 2016-10-25 |
| CN103937877B (zh) | 2016-09-28 |
| JP2013518579A (ja) | 2013-05-23 |
| WO2011095894A3 (en) | 2012-03-01 |
| EP2531858A4 (en) | 2013-08-07 |
| KR20120130329A (ko) | 2012-11-30 |
| CA2786974C (en) | 2018-05-01 |
| ES2660149T3 (es) | 2018-03-21 |
| CN103937877A (zh) | 2014-07-23 |
| AU2011212165B2 (en) | 2016-03-03 |
| ZA201205831B (en) | 2013-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201144807A (en) | Identification, assessment, and therapy of cancers with innate or acquired resistance to ALK inhibitors | |
| BR112016004305A2 (pt) | métodos diagnósticos e composições para tratamento de glioblastoma | |
| MX343368B (es) | Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer. | |
| MX2018008169A (es) | Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante. | |
| MX2011009690A (es) | Métodos y composiciones para trastornos relacionados con la proliferación celurar. | |
| CO7151491A2 (es) | Método para la identificación del origen de un cancer de origen primario desconocido | |
| EP2804960A4 (en) | BREAST CANCER BIOMARK SIGNATURES FOR INVASIVITY AND FORECAST | |
| BR112016002000A2 (pt) | Diagnóstico e terapia de câncer envolvendo células-tronco tumorais | |
| MX2014005800A (es) | Mutaciones del receptor notch humano y su uso. | |
| EA201792642A1 (ru) | Способы диагностики для т-клеточной терапии | |
| MX2015015605A (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| EA201400117A1 (ru) | Способы и нуклеиновые кислоты для определения прогноза у больных раком | |
| BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
| BR112014031414A2 (pt) | métodos de detectar doenças ou condições utilizando células doentes circulantes | |
| BR112016021383A2 (pt) | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo | |
| MX342966B (es) | Una mutacion mek1 que confiere resistencia a inhibidores raf y mek. | |
| BR112012026224A2 (pt) | métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia | |
| BR112015006705A8 (pt) | antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático e usos destes | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| BR112013004983A2 (pt) | método para a identificação e/ou monitoramento de câncer em um indivíduo, agente de formação de imagem in vivo, e , uso do mesmo | |
| IN2014DN08398A (enExample) | ||
| MX2019008005A (es) | Metodos y composiciones para diagnosticar preeclampsia. | |
| MX377026B (es) | Biomarcadores para la progresión de enfermedades en melanoma. | |
| BR112015027249A2 (pt) | método de diagnóstico de câncer | |
| BR112014023496A2 (pt) | mutantes c-raf que conferem resistência a inibidores de raf |